Aurinia Pharmaceuticals Inc. Income Statement
AUPH / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Aurinia Pharmaceuticals Inc. reported $283M in revenue and $287M in net income for FY2025. Revenue has grown at a 150.1% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $50.1M | $318.0K | $50.1M | $318.0K | $463.0K |
| Cost of Revenue | $32.7M | $28.2M | $14.1M | $0 | $0 | $0 | $0 | - |
| SG&A Expense | $101.8M | $172.0M | $195.0M | $97.3M | $22.3M | $97.3M | $22.3M | $13.7M |
| R&D Expense | $32.5M | $20.8M | $49.6M | $50.3M | $52.9M | $50.3M | $52.9M | $41.4M |
| Operating Income | $104.9M | -$4.7M | -$91.7M | -$104.3M | -$90.9M | -$104.3M | -$90.9M | -$55.2M |
| Interest Expense | - | - | $2.8M | - | - | - | - | - |
| Income Tax | -$173.0M | $1.7M | $551.0K | -$94.0K | $144.0K | -$94.0K | $144.0K | $73.0K |
| Net Income | $287.2M | $5.8M | -$78.0M | -$102.7M | -$88.4M | -$102.7M | -$88.4M | -$53.1M |
| EPS (Basic) | $2.14 | $0.04 | -$0.54 | -$0.87 | -$0.95 | - | -$0.95 | - |
| EPS (Diluted) | $2.07 | $0.04 | -$0.54 | -$0.87 | -$0.95 | -$0.63 | -$0.95 | -$0.63 |
| Shares Outstanding | 132.3M | 140.9M | 143.8M | 126.7M | 111.8M | 85.5M | 93.0M | 84.8M |
| Operating Margin | 37.1% | -2.0% | -52.2% | -208.1% | -28598.4% | -208.1% | - | -11930.9% |
| Profit Margin | 101.5% | 2.5% | -44.5% | -204.9% | -27794.0% | -204.9% | - | -11464.1% |